Kimura, S., Imagawa, J., Murai, K., Hino, M., Kitawaki, T., Okada, M., Tanaka, H., Shindo, M., Kumagai, T., Ikezoe, T., Uoshima, N., Sato, T., Watanabe, R., Kowata, S., Hayakawa, M., Hosoki, T., Ikeda, K., Kobayashi, T., Kakinoki, Y., Nishimoto, T., Takezako, N., Shibayama, H., Takaori-Kondo, A., Nakamae, H., Kawaguchi, A., Ureshino, H., Sakamoto, J., Ishida, Y., & , (2020). treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet, 7(3), e218–e225. http://access.bl.uk/ark:/81055/vdc_100101667476.0x00000d